Top Markets
Coin of the day
Histogen Inc. Histogen Inc.

Histogen Inc.

HSTO
株式のランク #40870
Histogen Inc. operates as a clinical-stage biotechnology company, focusing on... Histogen Inc. operates as a clinical-stage biotechnology company, focusing on the development of novel, stem cell-free biologic products derived from its proprietary hypoxia-generated growth factor technology platform. Among its offerings is HST-003, a human extracellular matrix, currently undergoing Phase 1/2 clinical trials to mend articular cartilage defects in the knee. Additionally, the company is advancing HST-004, a cell-conditioned media solution designed for spinal disc repair, and Emricasan, an orally active pan-caspase inhibitor targeting COVID-19 treatment. In its preclinical pipeline, Histogen is developing CTS-2090 and CTS-2096. These are selective caspase-1 inhibitors formulated to suppress inflammasome activation and intervene in a range of inflammation-mediated conditions. Founded in 2007, Histogen Inc. maintains its headquarters in San Diego, California.
株価
$0.02765
最終同期: 2024-12-23
時価総額
$69.04K
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 Histogen Inc. (HSTO)

カテゴリー

Histogen Inc.(HSTO)の利益
Sep 2023 時点の利益 TTM: $-12.38M
Histogen Inc. の最新の財務報告によると、同社の現在の利益は $-12.38M です。2021 年には $-15.01M の利益を上げ、これは 2020 年の利益 $-18.82M と 増加 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Histogen Inc. の利益の推移(2011 〜 2026)
各年末の利益
利益 変化
2026 (TTM) $-12.38M 16.35%
2022 $-10.64M -29.08%
2021 $-15.01M -20.24%
2020 $-18.82M 65.28%
2019 $-11.39M -36.79%
2018 $-18.01M 3.53%
2017 $-17.40M -41.49%
2016 $-29.73M 23.12%
2015 $-24.15M 8.19%
2014 $-22.32M 42.93%
2013 $-15.62M 78.48%
2012 $-8.75M -27.07%
2011 $-12.00M 0.00%
同業他社の利益
企業 利益 利益の差
$5.27B -42,694.48%
US
$1.95B -15,851.37%
NL
- -
CH
- -
KR
$3.01B -24,370.97%
BE